1-3 of 3
Laurie DiMiceli
Close
Sort by
Journal Articles

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Laurie DiMiceli, Swaminathan Padmanabhan, MD, David Lawrence, Zale P. Bernstein, MD, Kenichi Takeshita, MD, David Spaner, Paul Wallace, MD, Catriona Byrne, Cynthia Crystal, Myron S. Czuczman, MD
Journal: Blood
Blood (2005) 106 (11): 447.
https://doi.org/10.1182/blood.V106.11.447.447
Published: 2005
Journal Articles

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Swaminathan Padmanabhan, MD, Kena C. Miller, NP, Paula Pera, Laurie DiMiceli, Noreen Ersing, Paul Wallace, MD, Michael Rickert, Carl Porter, MD
Journal: Blood
Blood (2005) 106 (11): 2975.
https://doi.org/10.1182/blood.V106.11.2975.2975
Published: 2005
Journal Articles

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.

Laurie DiMiceli, RN, Kena C. Miller, NP, Michael Rickert, Paul Wallace, MD, Patricia Marshall, Dawn DePaolo, Swaminathan Padmanabhan, MD, Beverly Landrigan, RN, Asher A. Chanan-Khan, MD
Journal: Blood
Blood (2005) 106 (11): 5049.
https://doi.org/10.1182/blood.V106.11.5049.5049
Published: 2005